Clinical trials: HPV Infection, open to volunteers
EBV, HSV
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Background: Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses.
- Conditions
- EBV, HSV, VZV, HPV
- Trial name
- NCT01011712
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs.
- Conditions
- Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases
- Trial name
- NCT07756840
- Testing
- PRGN-2012, Bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 8 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
HPV (Human Papillomavirus)-Associated, Genital Warts
Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel
Phase II, a randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts by combination of CO2 laser and Geniwa gel compared to laser CO2 combined with gel placebo.
- Trial name
- NCT07698886
- Testing
- Geniwa gel
- Where
- Vietnam
- Volunteers
- 70 people
- Sponsor
- KTH Biopharma
HSIL, High Grade Squamous Intraepithelial Lesion, CIN 2
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2
This study evaluates the efficacy and safety of ALA-PDT versus LEEP in treating cervical HSIL/CIN2, aiming to demonstrate non-inferiority in clinical efficacy.
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesion, CIN 2, HPV (Human Papillomavirus)-Associated, Photodynamic Therapy (PDT)
- Trial name
- PDT for CIN2 (NCT07306260)
- Testing
- ALA-PDT, LEEP surgery
- Where
- 5 sites in China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HPV Infection, HIV Infections
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population.
- Conditions
- HPV Infection, HIV Infections, HPV-Related Malignancy
- Trial name
- NCT07087145
- Testing
- Mail-based Saliva Sample Kit, Study-related Surveys
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- University of California, San Francisco
Human Papillomavirus Infection, Anal HPV Infection
Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of Immunosuppression
Anal canal cancer is primarily associated with persistent infection by high-risk human papillomavirus (HR-HPV), particularly HPV-16.
- Conditions
- Human Papillomavirus Infection, Anal HPV Infection, Human Papillomavirus 16 Infection
- Trial name
- EPAHTOS (NCT07858201)
- Testing
- Anal Self-Sampling for High-Risk HPV Detection
- Volunteers
- 190 people
- Sponsor
- University Hospital, Montpellier
Cervical Cancer Screening, HPV Infection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in…
- Trial name
- NCT07850128
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 130,000 people
- Sponsor
- Karolinska Institutet
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9…
- Trial name
- NCT07824310
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster
- Where
- Indonesia
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Immunization, HPV Infection
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response.
- Conditions
- Immunization, HPV Infection, Human Papillomavirus
- Trial name
- NCT05672927
- Testing
- 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Human Papillomavirus (HPV) Vaccines
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low.
- Trial name
- NCT03429413
- Testing
- Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
- Where
- United States
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of Florida
HPV Infection, Vaccine Preventable Disease
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to…
- Trial name
- Add-Vacc (NCT04953130)
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cervix Cancer, HIV Infections
Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women Living With HIV
This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE)-3001-B trial aims to assess how the introduction of a…
- Conditions
- Cervix Cancer, HIV Infections, HPV Infection
- Trial name
- C-3001B-P-CS7 (NCT07624123)
- Testing
- Model 1- Screening in Clinic Only, Model 2 - Screening in Clinic and Community
- Where
- Zimbabwe
- Volunteers
- 17,734 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
HIV Infections, HPV Infection
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in…
- Conditions
- HIV Infections, HPV Infection, Cervix Cancer, CIN2
- Trial name
- ASCEND (NCT07545746)
- Testing
- 5% 5-fluorouracil Topical Cream
- Where
- 2 sites in Kenya
- Volunteers
- 140 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma
- Trial name
- SAVED (NCT07418034)
- Testing
- Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease
- Volunteers
- 132 people
- Sponsor
- University of Maryland, Baltimore
Cervical Cancer, Hpv
PopSci CHW4CervixHealth
Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients. Phase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a…
- Conditions
- Cervical Cancer, Hpv, Human Papilloma Virus, HPV Infection
- Trial name
- NCT07336134
- Testing
- Evalyn® Brush, Copan Floqswab, CHW4CervicalHealth
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
HPV, HPV - Anogenital Human Papilloma Virus Infection
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient…
- Trial name
- MIA-COMP (NCT07758140)
- Testing
- Mia by XytoTest, Rovers Cervex-Brush
- Where
- 11 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Mel Mont Medical
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Human Papillomavirus (HPV) Infection
HPV Detection Using Self-Collected Menstrual Blood
This study is evaluating whether human papillomavirus (HPV) can be accurately detected from self-collected menstrual blood samples.
- Trial name
- NCT07733557
- Testing
- Endometrics Menstrual Blood Collection Kit
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Samantha Batman
HIV, Chlamydia
National Rapid TLC: Testing and Linkage to Care
The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics.
- Conditions
- HIV, Chlamydia, Gonorrhea, HCV
- Trial name
- NCT07730801
- Testing
- Xpert® HIV-1 Qual XC
- Where
- 2 sites in Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto